Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caryn Lerman

Showing results (201-210 of 283) with videos related to

Pageof 29
Sort By:
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|November 4, 2011
Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trialsDavid P King, Sara Paciga, Eve Pickering, et al.
The American Journal on Addictions|May 18, 2016
Does cannabis use moderate smoking cessation outcomes in treatment-seeking tobacco smokers? Analysis from a large multi-center trialRachel A Rabin, Rebecca L Ashare, Robert A Schnoll, et al.
Drug and Alcohol Dependence|November 30, 2018
Lack of effect of transcranial direct current stimulation (tDCS) on short-term smoking cessation: Results of a randomized, sham-controlled clinical trialMary Falcone, Leah Bernardo, E Paul Wileyto, et al.
Addictive Behaviors|November 25, 2004
Effects of different nicotine replacement therapies on postcessation psychological responsesAndrew A Strasser, Vyga Kaufmann, Christopher Jepson, et al.
Pharmacogenetics and Genomics|April 13, 2012
DRD1 associations with smoking abstinence across slow and normal nicotine metabolizersWonho Lee, Riju Ray, Andrew W Bergen, et al.
Health Psychology : Official Journal of the Division of Health Psychology, American Psychological Association|November 16, 2002
A brief assessment of concerns associated with genetic testing for cancer: the Multidimensional Impact of Cancer Risk Assessment (MICRA) questionnaireDavid Cella, Chanita Hughes, Amy Peterman, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|August 27, 2005
Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trialsCaryn Lerman, Christopher Jepson, E Paul Wileyto, et al.
Molecular Genetics & Genomic Medicine|September 2, 2022
Risk-reducing mastectomy decisions among women with mutations in high- and moderate- penetrance breast cancer susceptibility genesJacob G Comeaux, Julie O Culver, John E Lee, et al.
JCO Clinical Cancer Informatics|December 8, 2022
Development of Machine Learning Algorithms Incorporating Electronic Health Record Data, Patient-Reported Outcomes, or Both to Predict Mortality for Outpatients With CancerRavi B Parikh, Jill S Hasler, Yichen Zhang, et al.
Health Psychology : Official Journal of the Division of Health Psychology, American Psychological Association|October 23, 2003
Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trialCaryn Lerman, Peter G Shields, E Paul Wileyto, et al.
Pageof 29

Showing results (201-210 of 283) with videos related to

Sort By:
Pageof 29
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|November 4, 2011
Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trialsDavid P King, Sara Paciga, Eve Pickering, et al.
The American Journal on Addictions|May 18, 2016
Does cannabis use moderate smoking cessation outcomes in treatment-seeking tobacco smokers? Analysis from a large multi-center trialRachel A Rabin, Rebecca L Ashare, Robert A Schnoll, et al.
Drug and Alcohol Dependence|November 30, 2018
Lack of effect of transcranial direct current stimulation (tDCS) on short-term smoking cessation: Results of a randomized, sham-controlled clinical trialMary Falcone, Leah Bernardo, E Paul Wileyto, et al.
Addictive Behaviors|November 25, 2004
Effects of different nicotine replacement therapies on postcessation psychological responsesAndrew A Strasser, Vyga Kaufmann, Christopher Jepson, et al.
Pharmacogenetics and Genomics|April 13, 2012
DRD1 associations with smoking abstinence across slow and normal nicotine metabolizersWonho Lee, Riju Ray, Andrew W Bergen, et al.
Health Psychology : Official Journal of the Division of Health Psychology, American Psychological Association|November 16, 2002
A brief assessment of concerns associated with genetic testing for cancer: the Multidimensional Impact of Cancer Risk Assessment (MICRA) questionnaireDavid Cella, Chanita Hughes, Amy Peterman, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|August 27, 2005
Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trialsCaryn Lerman, Christopher Jepson, E Paul Wileyto, et al.
Molecular Genetics & Genomic Medicine|September 2, 2022
Risk-reducing mastectomy decisions among women with mutations in high- and moderate- penetrance breast cancer susceptibility genesJacob G Comeaux, Julie O Culver, John E Lee, et al.
JCO Clinical Cancer Informatics|December 8, 2022
Development of Machine Learning Algorithms Incorporating Electronic Health Record Data, Patient-Reported Outcomes, or Both to Predict Mortality for Outpatients With CancerRavi B Parikh, Jill S Hasler, Yichen Zhang, et al.
Health Psychology : Official Journal of the Division of Health Psychology, American Psychological Association|October 23, 2003
Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trialCaryn Lerman, Peter G Shields, E Paul Wileyto, et al.
Pageof 29